SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-005076 to Cano Health, Inc. (CIK 0001800682)

Cano Health, Inc. (CIK 0001800682)
Date: May 12, 2023 · CIK: 0001800682 · Accession: 0000000000-23-005076

AI Filing Summary & Sentiment

Date
May 12, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Cano Health, Inc. (CIK 0001800682)

Letter

United States securities and exchange commission logo May 12, 2023 Marlow Hernandez, MD Chief Executive Officer Cano Health, Inc. 9725 NW 117th Ave, Suite 200 Miami, FL 33178 Re:Cano Health, Inc. Schedule 13D/A filed by Dr. Marlow Hernandez et al. Filed April 6, 2023 File No. 005-91632 Dear Marlow Hernandez: We have reviewed the above-captioned filing, and have the following comments. Please respond to this letter by amending the filing or by providing the requested information. If a belief exists that our comments do not apply to the facts and circumstances or that an amendment is inappropriate, please advise us why in a response letter. After reviewing any amendment to the filing and any information provided in response to these comments, we may have additional comments. Schedule 13D/A filed April 6, 2023 General 1.We note the Amendment No. 3 to Schedule 13D filed on April 6, 2023 by Dr. Hernanandez disclosing the transfer of shares under the Repayment Agreement. The Repayment Agreement reportedly was repaying a secured promissory note dated February 28, 2022 between Dr. Hernandez, Hernandez Borrower Holdings LLC and Robert Comerlinck. Item 6 of Schedule 13D requires the disclosure of any contracts between filers and "any person with respect to any securities of the issuer including loan or option arrangements." Item 7 of Schedule 13D also requires the filing of any agreement disclosed in Item 6. Please advise us, with a view towards revised disclosure, how Dr. Hernandez complied, if at all, with the above disclosure requirements. 2.We note the Repayment Agreement grants an option to certain executive officers to repurchase the shares of Cano Health transferred to Mr. Comerlinck pursuant to the Agreement and contains certain prohibitions on Mr. Camerlinck's ability to transfer shares of Cano that are subject to the option. Notwithstanding the definition of a "person" under

FirstName LastNameMarlow Hernandez, MD Comapany NameCano Health, Inc. May 12, 2023 Page 2 FirstName LastName Marlow Hernandez, MD Cano Health, Inc. May 12, 2023 Page 2 Section 3(a)(9) of the Securities Exchange Act of 1934, application of Section 13(d)(3) also results in two or more persons being regulated as as single "person" under Section 13(d)(1) if they "act as" a group for the purpose of acquiring, holding or disposing of a voting class of Section 12 registered equity securities. Therefore, each member of the group bears an obligation to report beneficial ownership on behalf of the group under Rule 13d-1(k). Accordingly, please revise the associated Schedule 13D to check the appropriate box in Item 2 and identify all group members. Alternatively, please confirm, if true, that the above individuals are not acting as a group within the meaning of Section 13(d)(3). 3.We note the disclosure on line 7 of the cover page that Dr. Hernandez has Sole Voting Power of "25,108,418" shares. Footnote 1 indicates that reported amount includes the option to acquire 8,536,936 shares of Class B transferred to Mr. Camerlinck pursuant to the Repayment Agreement. Please advise, with a view towards revised disclosure, how Dr. Hernandez exercises sole voting power over these shares. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Michael Killoy at (202) 551-7576 or Nicholas Panos at (202) 551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions cc: Amanda Fenster, Esq.

Show Raw Text
United States securities and exchange commission logo
May 12, 2023
Marlow Hernandez, MD
Chief Executive Officer
Cano Health, Inc.
9725 NW 117th Ave, Suite 200
Miami, FL 33178
Re:Cano Health, Inc.
Schedule 13D/A filed by Dr. Marlow Hernandez et al.
Filed April 6, 2023
File No. 005-91632
Dear Marlow Hernandez:
            We have reviewed the above-captioned filing, and have the following comments.
             Please respond to this letter by amending the filing or by providing the requested
information. If a belief exists that our comments do not apply to the facts and circumstances or
that an amendment is inappropriate, please advise us why in a response letter.
             After reviewing any amendment to the filing and any information provided in response
to these comments, we may have additional comments.
Schedule 13D/A filed April 6, 2023
General
1.We note the Amendment No. 3 to Schedule 13D filed on April 6, 2023 by Dr.
Hernanandez disclosing the transfer of shares under the Repayment Agreement.  The
Repayment Agreement reportedly was repaying a secured promissory note dated February
28, 2022 between Dr. Hernandez, Hernandez Borrower Holdings LLC and Robert
Comerlinck.  Item 6 of Schedule 13D requires the disclosure of any contracts between
filers and "any person with respect to any securities of the issuer including loan or option
arrangements."  Item 7 of Schedule 13D also requires the filing of any agreement
disclosed in Item 6.  Please advise us, with a view towards revised disclosure, how Dr.
Hernandez complied, if at all, with the above disclosure requirements.
2.We note the Repayment Agreement grants an option to certain executive officers to
repurchase the shares of Cano Health transferred to Mr. Comerlinck pursuant to the
Agreement and contains certain prohibitions on Mr. Camerlinck's ability to transfer shares
of Cano that are subject to the option.  Notwithstanding the definition of a "person" under

 FirstName LastNameMarlow Hernandez, MD
 Comapany NameCano Health, Inc.
 May 12, 2023 Page 2
 FirstName LastName
Marlow Hernandez, MD
Cano Health, Inc.
May 12, 2023
Page 2
Section 3(a)(9) of the Securities Exchange Act of 1934, application of Section 13(d)(3)
also results in two or more persons being regulated as as single "person" under Section
13(d)(1) if they "act as" a group for the purpose of acquiring, holding or disposing of a
voting class of Section 12 registered equity securities.  Therefore, each member of the
group bears an obligation to report beneficial ownership on behalf of the group under Rule
13d-1(k).  Accordingly, please revise the associated Schedule 13D to check the
appropriate box in Item 2 and identify all group members.  Alternatively, please confirm,
if true, that the above individuals are not acting as a group within the meaning of Section
13(d)(3).
3.We note the disclosure on line 7 of the cover page that Dr. Hernandez has Sole Voting
Power of "25,108,418" shares.  Footnote 1 indicates that reported amount includes the
option to acquire 8,536,936 shares of Class B transferred to Mr. Camerlinck pursuant
to the Repayment Agreement.  Please advise, with a view towards revised disclosure, how
Dr. Hernandez exercises sole voting power over these shares.
            We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please direct any questions to Michael Killoy at (202) 551-7576 or Nicholas Panos at
(202) 551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions
cc:       Amanda Fenster, Esq.